Cardiovascular Drugs Market – Market Trends and Analysis Market Analysis
Cardiovascular Drugs Market Overview
The global cardiovascular drugs market is expected to continue its growth in the coming years due to increased prevalence of heart diseases and other cardiovascular-related diseases. With heart diseases and the number of diabetic patients on the rise, cardiovascular drugs market size is expected to expand, opening up new growth avenues for existing participating members and new market entrants.
Among the drugs used to treat cardiovascular diseases, the heart failure drugs market is one in particular expected to witness strong growth through 2022 due to the growing prevalence of chronic diseases such as diabetes. The lack of awareness and diabetes treatment facilities in regions like Africa is resulting in an increased number of diabetic patients. The diabetic population is increasing in countries such as the US, China, and India, which in turn, is driving the adoption rate of congestive heart failure drugs. Due to these factors, we forecast the global heart failure drugs market to grow at a CAGR of 10% between 2018-2022. Other insights provided within Technavio’s cardiovascular drugs market reports include:
Cardiovascular Drugs Market Insights and Statistics
- The global hypertension drugs market will post an impressive market value of USD 32 billion by the end of 2020. The prevalence of hypertension is high among the older population with close to 70% of the patients with high BP above the age of 60.
- The global angina pectoris drugs market will grow at a CAGR of 4% between 2017-2021. The growth of this market will be attributed to market participants developing novel therapeutic agents to meet the unmet demand for therapeutics in the angina treatment market.
Cardiovascular Drugs Market Share and Segmentation
Within our cardiovascular drugs industry research, we provide deep insights into the market landscape, its segments, and their market share. Our research experts segment this market by major cardiovascular disease types such as congenital heart disease, coronary artery disease, hypertension, heart failure, and more. The heart failure drugs segment, in particular, is witnessing strong growth owing to an increased number of diabetic patients, with the majority of the diabetic population being in countries such as the US, China, and India.
Within the cardiovascular drugs market, our research analysis focuses on the latest developments and clinical trials for cardiovascular drugs and the cardiovascular diseases in which they treat. Our areas of expertise include research areas such as:
- Cardiovascular disease market
- Congenital heart disease market
- Cyanotic heart disease market
- Arrhythmia (irregular heartbeat) market
- Tachycardia market
- Bradycardia market
- Atrial fibrillation market
- Coronary artery disease market
- Dilated cardiomyopathy market
- Hypertrophic cardiomyopathy market
- Mitral valve prolapse market
- Pulmonary stenosis market
- Heart failure market
- Beta blockers
- Angiotensin II receptor blockers (ARBs)
- Angiotensin-converting enzyme (ACE)
- Hypertension market
- Systemic hypertension drugs
- Pulmonary hypertension drugs
- Angina pectoris market
- Calcium channel blockers
- Nitrates
- Angiotensin-converting enzyme inhibitors
- Myocardial infarction drugs (heart attack) market
- Brand-name drugs
- Generic drugs
- Dyslipidemia drugs market
- Statins
- Cholesterol absorption inhibitors
- Dyslipidemia injectables
- Congenital heart disease market
We at Technavio, with our comprehensive understanding of the cardiovascular market, have been monitoring the latest industry trends to develop an in-depth portfolio of cardiovascular market reports that are based on a broad knowledge of this healthcare sphere. Our market research portfolio covers the following:
- Cardiovascular drugs market trends
- Cardiovascular drugs market growth
- Cardiovascular drugs market size
- Cardiovascular drugs market share
- Cardiovascular drugs industry statistics
- Cardiovascular drugs market drivers and challenges
In addition to market research analysis of cardiovascular disease types, we also monitor and track the latest developments for clinical trials of cardiovascular drugs. Our cardiovascular drugs pipeline analysis reports cover the major developments for new and better drugs that will be used for the treatment various cardiovascular diseases including ischemic heart disease, stroke, peripheral vascular disease, heart failure, rheumatic heart disease, and congenital heart disease. In our recent pipeline analysis report for congenital heart disease, our research analysts predict that with the introduction of promising approaches for surgery or cardiac catheterization and heart transplantation, the global congenital heart disease market will witness growth in the over the next few years.
Cardiovascular Drugs Clinical Trials
Technavio keeps itself abreast of the latest developments in the cardiovascular drugs pipeline by tracking clinical cardiovascular research trials across the globe. Trials for coronary artery disease, heart disease, and heart failure, are some of the most popular ongoing cardiovascular drugs clinical trials.
Cardiovascular drug clinical trials are used as a proving ground for developing new or better drugs and vaccines to treat cardiovascular diseases. Our cardiovascular clinical trials analysis encompasses all phases of development starting from discovery projects to phase 1, phase 2, and phase 3 of clinical trials, ending with the registration of new drugs.
Cardiovascular Drugs Clinical Trials – Pipeline Analysis Reports
- Beta blockers for cardiovascular Disease treatment - A Pipeline Overview Report
- Myocarditis - A Pipeline Analysis Report
- Chronic Heart Failure - A Pipeline Overview Report
- Atrial Fibrillation - A Pipeline Overview Report
- Hypertension -Pipeline Overview
- Congenital Heart Disease - A Pipeline Analysis Report
